Overview
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2015 on request of the Sponsor.
On 10 June 2003, orphan designation (EU/3/03/144) was granted by the European Commission to Barrier Therapeutics NV, Belgium, for liarozole for the treatment of congenital ichthyoses.
The sponsorship was transferred to Stiefel Laboratories (U.K.) Limited, United Kingdom, in June 2010.
Key facts
Active substance |
Liarozole
|
Intended use |
Treatment of congenital ichthyoses
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/03/144
|
Date of designation |
10/06/2003
|
Sponsor |
Stiefel Laboratories (U.K.) Limited
Eurasia Headquarters Concorde Road Maidenhead SL6 4BY United Kingdom Telephone: +44 1628 612 260 Telefax: +44 1628 612 000 E-mail: Helen.barker@stiefel.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: